Why Is MIRA Pharmaceuticals Stock Gaining Tuesday?
MIRA Pharmaceuticals (NASDAQ: MIRA) stock jumps as MIRA-55 meets key preclinical study milestones for non-opioid inflammatory pain relief.
Stocks · News reference
MIRA Pharmaceuticals Announces New Preclinical Data On Mira-55 Cannabinoid Analog In Development For Chronic Inflammatory Pain Showing Favorable Anxiety-Reducing Effect While Delivering Pain Relief
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
MIRA Pharmaceuticals shares are trading higher after the company announced results from the completed 7-day dose-range finding toxicology and toxicokinetic studies of MIRA-55 in rats and dogs.
MIRA Pharmaceuticals Says 7-Day Dose-Range Finding Toxicology Studies Of MIRA-55 In Rats And Dogs Completed, Supporting Next Phase Of IND-Enabling Program; Targets IND Submission In Q1 2027
8-K filing — MIRA PHARMACEUTICALS, INC. (MIRA)
Filed: 2026-09-01 AccNo: 0001493152-26-040930 Size: 238 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits